行情

OCUL

OCUL

Ocular
NASDAQ

实时行情|Nasdaq Last Sale

4.520
-0.170
-3.62%
盘后: 4.520 0 0.00% 16:00 01/24 EST
开盘
4.700
昨收
4.690
最高
4.860
最低
4.450
成交量
93.70万
成交额
--
52周最高
5.55
52周最低
2.350
市值
2.17亿
市盈率(TTM)
-2.5136
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OCUL 新闻

  • 玩游戏了解流行病?单机游戏“瘟疫公司”多国畅销
  • 新京报网.2小时前
  • 携程升级重大灾害保障金至2亿
  • 36氪.3小时前
  • 新东方向湖北省红十字会捐款2000万元
  • 新浪科技.5小时前
  • 苹果与博通签订两份合作协议 后者有望赚150亿美元
  • 新浪科技.6小时前

更多

所属板块

医疗设备、用品及经销
-0.74%
医疗设备和用品
-0.90%

热门股票

名称
价格
涨跌幅

OCUL 简况

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
展开

Webull提供Ocular Therapeutix Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。